Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Erythropoietic Protoporphyria

Erythropoietic Protoporphyria

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Erythropoietic Protoporphyria

10 trials tracked for Erythropoietic Protoporphyria: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 277 citations.

10Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 5 Phase 2 3 Other / NA 2
  1. Phase 3 Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) Completed · 277 cited
  2. Phase 3 Phase III Confirmatory Study in Erythropoietic Protoporphyria Completed · 277 cited
  3. Phase 3 Multicentre Phase III Erythropoietic Protoporphyria Study Completed
  4. Phase 3 Sorbent Therapy of the Cutaneous Porphyrias Completed
  5. Phase 3 A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) Completed
  6. Phase 2 Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients Completed
Show 4 more trials
  1. Phase 2 Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP Completed
  2. Phase 2 Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) Completed
  3. N/A Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact Completed
  4. N/A Oral Iron for Erythropoietic Protoporphyrias Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 2 trial shows bitopertin reduces protoporphyrin-IX in adults with erythropoietic protoporphyria
Gastroenterology RCT
Phase 2 trial shows bitopertin reduces protoporphyrin-IX in adults with erythropoietic protoporphyria Experimental drug bitopertin reduces key protein in adults with light sensitivity disorder
In a phase 2 randomized controlled trial of 75 adults with erythropoietic protoporphyria, once-daily oral bitopertin (20 mg or 60 mg) signif…
A new oral drug significantly lowers the protein causing painful light sensitivity in adults with a rare disorder, reducing skin reactions a…
Apr 3, 2026